


以ADC為核心的精準癌症治療產品線



產品	標靶	關鍵技術	載荷體 (抗體藥物比)	適應症
OBI-992	TROP2 單抗	半胱胺酸鍵結	Exatecan (DAR4)	實體腫瘤
OBI-902	TROP2 單抗	醣鍵結 via GlycOBI®	Exatecan (DAR4)	實體腫瘤
OBI-904	Nectin-4 單抗	醣鍵結 via GlycOBI®	Exatecan (DAR8)	實體腫瘤 軟組織瘤
OBI-201	TROP2 x HER2 雙抗	醣鍵結 via GlycOBI®	Exatecan (DAR4)	實體腫瘤
OBI-221	c-MET x HER3 雙抗雙藥	醣鍵結 via GlycOBI DUO®	Exatecan & MMAE (DAR 8: 2)	實體腫瘤
OBI-3424 [§]	AKR1C3 前驅型藥物	N/A	N/A	肝癌 (HCC) [†]




Apr, 2026

* GlycOBI® 與 GlycOBI DUO® 為浩鼎專有醣鍵結技術且為浩鼎的專利商標
 † 臨床試驗由深圳艾欣達偉醫藥科技有限公司進行
 § 浩鼎擁有OBI-3424 在全球的獨家權利(不包括以下之地區: 中國、香港、澳門、台灣、日本、南韓、新加坡、馬來西亞、泰國、土耳其、印度)。



ADC-Centric Pipeline in Precision Oncology



Product	Target	Technology	Payload (DAR)	Indication	Preclinical	IND enabling	P1	P2	P3
OBI-992	TROP2 monospecific	Cysteine conjugation	<i>Exatecan (DAR4)</i>	Solid Tumors	Phase 1 ↗ NCT06480240				
OBI-902	TROP2 monospecific	Glycan conjugation via GlycOBI [®]	<i>Exatecan (DAR4)</i>	Solid Tumors	Phase 1 ↗ NCT07124117				
OBI-904	Nectin-4 monospecific	Glycan conjugation via GlycOBI [®]	<i>Exatecan (DAR8)</i>	Solid and Soft Tissue Tumors	IND enabling				
OBI-201	TROP2 x HER2 bispecific	Glycan conjugation via GlycOBI [®]	<i>Exatecan (DAR4)</i>	Solid Tumors	Pre-clinical				
OBI-221	c-MET x HER3 bispecific dual payload	Glycan conjugation via GlycOBI DUO [®]	<i>Exatecan & MMAE (DAR 8: 2)</i>	Solid Tumors	Pre-clinical				
OBI-3424[§]	AKR1C3 prodrug	N/A	N/A	Liver (HCC) [†]	Phase 2				

Apr, 2026

* **GlycOBI**[®] and **GlycOBI DUO**[®] are patented glycan-based technologies and are registered trademarks of OBI Pharma Inc.

[†] Clinical study conducted by Asentawits Pharma (China)

[§] OBI owns global rights excluding China, Hong Kong, Macau, Taiwan, Japan, Korea, Singapore, Malaysia, Thailand, Turkey, and India.

